secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059315
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis completes Phase III data unblinding for buntanetap; topline expected June
--------------------------------------------------------------------------------

- Unblinding of Phase III study of buntanetap in early Parkinson's disease completed.
- Topline efficacy data expected in June 2024.
- Delay due to PK measurement error resolved; repeated analysis showed correct 33% blank samples.
- Company confident in data integrity and ready for evaluation with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924059315/0001104659-24-059315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924059315/tm2414019d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer